Last $5.29 USD
Change Today +0.065 / 1.25%
Volume 119.3K
PGNX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 10:17 AM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

progenics pharmaceuticals (PGNX) Snapshot

Open
$5.27
Previous Close
$5.32
Day High
$5.32
Day Low
$5.24
52 Week High
01/17/14 - $7.45
52 Week Low
05/9/14 - $3.10
Market Cap
367.6M
Average Volume 10 Days
753.0K
EPS TTM
$-0.62
Shares Outstanding
69.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PROGENICS PHARMACEUTICALS (PGNX)

progenics pharmaceuticals (PGNX) Related Businessweek News

No Related Businessweek News Found

progenics pharmaceuticals (PGNX) Details

Progenics Pharmaceuticals, Inc. develops medicines for oncology. The company offers Relistor-subcutaneous injection for the treatment of opioid induced constipation (OIC) in advanced-illness patients receiving palliative care when laxative therapy has not been sufficient; and for treatment of OIC inpatients with non-cancer pain. It also develops Relistor-oral that is in Phase III testing for the treatment of OIC. In addition, the company’s clinical-stage product candidates include prostate specific membrane antigen (PSMA) antibody-drug conjugate, which has completed Phase II testing in chemotherapy-experienced patients and is ongoing second cohort in chemotherapy-naïve patients for the treatment of prostate cancer; 1404, a radio-labeled small molecule that has completed Phase II testing, as well as acts as an imaging agent to diagnose and detect prostate cancer; and Azedra, a radiotherapeutic product candidate, which is in Phase IIb registrational trial under special protocol assessment for the treatment of pheochromocytoma and paraganglioma. Further, it develops MIP-1095, a PSMA-targeted small molecule radiopharmaceutical that is in clinical development stage for the treatment of prostate cancer. The company has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide other than Japan; and collaboration agreement with Seattle Genetics, Inc. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in Tarrytown, New York.

69 Employees
Last Reported Date: 03/13/14
Founded in 1986

progenics pharmaceuticals (PGNX) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: $535.6K
Principal Financial Officer, Principal Accoun...
Total Annual Compensation: $279.6K
Executive Vice President of Medical Affairs
Total Annual Compensation: $426.5K
Senior Vice President of Manufacturing
Total Annual Compensation: $296.5K
Executive Vice President of Research and Deve...
Total Annual Compensation: $212.5K
Compensation as of Fiscal Year 2013.

progenics pharmaceuticals (PGNX) Key Developments

FDA Assigns September 29, 2014 Prescription Drug User Fee Act Goal Date for Salix Pharmaceuticals's RELISTOR(R) Subcutaneous Injection sNDA for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain

Salix Pharmaceuticals Ltd. and Progenics Pharmaceuticals announced that the Food and Drug Administration (FDA or Agency) has informed Salix that the supplemental New Drug Application (sNDA) for RELISTOR(R) (methylnaltrexone bromide) Subcutaneous Injection, 20 mg/ml, for the treatment of opioid-induced constipation (OIC) in patients taking opioids for chronic non-cancer pain has been assigned a user fee goal date of September 29, 2014. On July 10, 2014 the FDA Office of Drug Evaluation III responded to the Company's formal appeal filed in response to the Complete Response Letter (CRL) of July 27, 2012 to the supplemental NDA (sNDA) for RELISTOR. The Agency's letter stated that, 'Salix's request that FDA approve the supplemental NDA for RELISTOR subcutaneous injection for the treatment of opioid-induced constipation in patients with chronic non-cancer pain based on the submitted data is granted'. In regard to the RELISTOR sNDA the Agency directed Salix to work with and submit certain information to the Division of Gastroenterology and Inborn Errors Products (DGIEP). On July 29, 2014 the FDA accepted Salix's resubmission. On August 8, 2014 the FDA communicated to Salix that the Company's resubmission is a complete, class 1 response to the FDA's action letter and assigned the user fee goal date. Opioid analgesics are frequently prescribed for patients with chronic pain, including patients with advanced illness. An estimated 27 million patients in the US are on opioids for chronic pain. Constipation is one of the most common and distressing side effects in patients receiving chronic opioid therapy. Approximately 40% of chronic pain patients, or nearly 11 million patients, on opioid therapy will experience OIC. RELISTOR is the first approved medication that specifically targets the underlying cause of OIC. RELISTOR is a Peripherally Acting Mu Opioid Receptor Antagonist (PAMORA) specifically designed to block the constipating effects of opioids in the gastrointestinal tract. The unique molecular structure of RELISTOR restricts it from crossing the blood brain barrier and interfering with the analgesic effect of opioids. In clinical trials, approximately 50% of patients experienced relief of OIC in as little as 4 hours. RELISTOR is the only PAMORA currently approved by the FDA for the treatment of OIC in patients with advanced illness receiving palliative care when the response to laxatives has been insufficient.

Progenics Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Progenics Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenues of $1.477 million compared to $1.801 million a year ago, reflecting decreased collaboration revenue of $0.4 million and increased royalty income of $0.2 million. Operating loss was $11.087 million compared to $12.273 million a year ago. Net loss before income tax benefit was $11.074 million compared to $12.263 million a year ago. Net loss was $11.073 million or $0.17 per basic and diluted share compared to $12.263 million or $0.24 per basic and diluted share a year ago. For the six months, the company reported total revenues of $3.292 million compared to $4.027 million a year ago. Operating loss was $20.412 million compared to $23.545 million year ago. Net loss was $20.386 million or $0.31 per basic and diluted share compared to $23.521 million or $0.46 per basic and diluted share a year ago.

Progenics Pharmaceuticals, Inc., Q2 2014 Earnings Call, Aug 08, 2014

Progenics Pharmaceuticals, Inc., Q2 2014 Earnings Call, Aug 08, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PGNX:US $5.29 USD +0.065

PGNX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CTI BioPharma Corp $2.64 USD -0.0189
Dynavax Technologies Corp $1.36 USD +0.01
Rigel Pharmaceuticals Inc $2.14 USD -0.09
Transgene SA €8.35 EUR +0.02
ZIOPHARM Oncology Inc $2.99 USD +0.02
View Industry Companies
 

Industry Analysis

PGNX

Industry Average

Valuation PGNX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 46.7x
Price/Book 3.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 39.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROGENICS PHARMACEUTICALS, please visit www.progenics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.